Navigation Links
Study finds primary care depression treatment often does not follow quality guidelines
Date:9/4/2007

Most patients with depression who are treated by primary care physicians do not receive care consistent with quality standards, according to a new RAND Corporation study.

Physicians had high rates of adherence to just one third of the 20 measures of quality that researchers examined and had low rates of adherence to nearly half of the treatment recommendations studied, according to the report in the September 4 edition of the Annals of Internal Medicine.

"These findings are important for patients since most cases of depression are diagnosed and treated in primary care settings," said senior author Dr. Lisa V. Rubenstein, the study's senior author, and a senior scientist at RAND, a nonprofit research organization, and a physician at the Veterans Affairs Greater Los Angeles Healthcare System. "This shows that additional efforts are needed to improve the treatment of depression."

The study also found that patients who received better-quality care reported fewer symptoms of depression up to two years after the start of treatment. The findings are among the first linking quality guidelines for depression treatment with improved patient outcomes in community settings.

"These are initial findings, but they suggest that programs that encourage doctors to follow treatment guidelines can help improve the long-term outlook for people with depression," said Rubenstein, who also is affiliated with the David Geffen School of Medicine at UCLA.

Previous studies have shown that primary care providers do a poor job following guidelines for antidepressant use or psychotherapy. The RAND study is one of the first to assess primary care providers' adherence to a comprehensive set of treatment guidelines for depression.

Researchers from RAND Health examined the experiences of health care providers and patients who took part from 1996 to 1998 in the Quality Improvement for Depression collaboration, which was designed to
'/>"/>

Contact: Warren Robak
robak@rand.org
310-451-6913
RAND Corporation
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Gene study links endometriosis, infertility
2. Study reveals how stress can make you sick
3. Study points out that HIV vaccine may not be accepted easily
4. A new study surpasses Gene Therapy Hurdle
5. Tomato Sauce reduces Cancer Risk- Study
6. A question on study of Adult Stem Cell
7. Study on obesity and heart failure
8. National Lung Study in the process
9. Marijuana gateway theory strengthened by study of twins
10. Old theory of adaptation confirmed by new study
11. Study casts doubt on keyboard ills

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...wswire-USNewswire/--WhenmostpeopleheartheacronymTM...ivepatientsthehelptheyneed.TMJstandsfortheTemporal...acts/connectswithyourskull(temporalbone). ,, Th...painwithchewing,clickingorpoppingofthejaw.Butmanyo...:headaches,fatigue,sleepdisturbances,irritability,...
(Date:11/25/2009)...5/PRNewswire-FirstCall/-- OnyxPharmaceuticals,Inc...sttwoinvestoreventsinDecember: ,, ASHBriefing... ,, Principalinvestigatorswilldiscussdatapresen...ctorymultiplemyeloma,asfeaturedatthe51stAmericanSo...NewOrleans,LA.Theteleconferencewillbeginat9:00a.m....
(Date:11/25/2009)...re/-SentinelleMedicalInc.,aleadingmanufacturerofbr...esasuiteofnewleadingedgeclinicalapplicationsonitsA...RadiologicalSocietyofNorthAmerica(RSNA)annualmeeti...applicationsleveragetheuniquehighqualityimagesgene...pportmultipleimagingmodalitiesformulti-parametrica...
(Date:11/25/2009).../PRNewswire-USNewswire/--AnarticlebyJanetWoodcock,...esearch,titled"ADifficultBalance-PainManagement,Dr...TheNewEnglandJournalofMedicine. ,, (Logo: http:...,, Inthearticle,WoodcockdiscussesFDAeffortstost...honeeditandmanagingtherisksposedbyvariousanalgesic...
(Date:11/25/2009)...ewswire/--TheBayAreaAirQualityManagementDistrictis...Air Alert forThursday,November26,2009whichban...el,bothindoorsandoutdoors. ,, "Cold,stillweathe...JackBroadbent,executiveofficeroftheAirDistrict."We...neighborsandfellowcommunitymembersthisThanksgiving...
Breaking Medicine News(10 mins):Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2
...ore research is being published showing the benefi...l tolerated by most patients due to the aftertaste...hers at Banner now say they have developed a chewa...oft chewable shell that can be taken without water...
... medications available , one must also be wary of ...ng to the Drug Control Department, 63 batches of s...killers and cardiac medicines, are being sold in B... drug racket first came to light in May-end this y...
...n B9 has been known to help in the brain developme...e to this reason it is administered to pregnant wo...ngen University, Netherlands has proposed that thi... increased levels of homocysteine. This amino acid...
... Lancet investigated the efficacy of acupuncture c...puncture in patients with osteoarthritis of the kn...reat many types of patients with chronic pain. ...o the acupuncture group, second group with 76 pati...
...able to stop the geriatric population from falling...ntain their balance. The device is called Yak...e that conforms to the footwear and helps the peop...of the number of falls they have on wearing the de...
...rom peripheral arterial disease may lose their lim...s to attend to them. Research findings report that...r surgeons, report less number of cases where pati...ften the only symptom experienced is a recurring p...
Other Medicine News:
(Date:11/25/2009)...ire-FirstCall/--Formanyofthemillionsofhearingimpai...ated hearingloss ,theholidaysmaynotbeallthathappy,...cepresidentofHearUSA(Amex: EAR ),oneofAmerica,slar...eshavelinkedhearinglosstostress,frustration,andsoc...gatheringswithfamiliesandfriends,whenmanyofthosewi...
(Date:11/25/2009)...tlinker.comannouncesthatanewmarketresearchreportis...DevicesMarketAnalysisandForecaststo2015 ,, ht...ental-Devices-Market-Analysis-and-Forecasts-to-201...sisandForecaststo2015 ,, Summary ,, Thisre...tarelatingtotheUSdentaldevicesmarket.Italsooffersd...
(Date:11/25/2009)...all/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicec...ptivesurgicaltreatmentsforthespine,announcedtodayt...09,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfo...pany,sproductsandwillincludecommentsfrommanagement...nnumbersare1-877-407-4018fordomesticcallersand1-20...
Breaking Medicine Technology:For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3A Mediterranean Approach to Flavorful Living 56023 1A Mediterranean Approach to Flavorful Living 56023 2A Mediterranean Approach to Flavorful Living 56023 3Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 1Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 2Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 3Pfizer Pays a Record Amount to Settle Federal and State Fraud Investigations Into Illegal Off Label Marketing Practices 56020 4eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 1eDiets com Selects Karlin+Pimsler to Lead Creative Turnaround 56017 2
...groups show dose-dependent PSA d... call to be held today at 8:30 A.M. Eastern time -...: MDVN ) today announced that its selective andro...ed serum levels of prostate specific,antigen (PSA)...rolled in,the first two dose groups of its ongoing...
...ustained virologic response in non-respond...results in line with previous studies of long-acti...th less frequent dosing -, - Final data from Phas..., Annual Meeting of the American Association for t... (AASLD) -, ROCKVILLE, Ma., Nov. 5 Human G...
Other Medicine Technology:Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 2Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 3Medivation's MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
Hi-Top Post Op Shoe
EZY Close
Forefoot Reliever
Ultra 90 Fixed Plantar Fasciitis Splint
Medicine Products: